PDCD1 and lymphoma: In the case of lymphoma, the approval of PD1 targeted drugs including pembrolizumab and nivolumab for the treatment of Hodgkin’s Lymphoma (HL) and nasal NK-T cell lymphomas has represented an incremental improvement in these diseases, though the activity of these checkpoint inhibitors has not been seen across the greater diversity of NHL3–5.